Zhengye Biotechnology Holding Limited (ZYBT) Stock Score, Valuation & Financial Research
Zhengye Biotechnology Holding Limited is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 15/100.
Quick answer for ZYBT
Zhengye Biotechnology Holding Limited currently has a Wall Street Score of 15/100. The stored market price is $1.38. Its financial score is 12/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Zhengye Biotechnology Holding Limited does
Zhengye Biotechnology Holding Limited specializes in the creation, manufacturing, and commercialization of animal health immunizations. The company primarily supplies the Chinese agricultural sector with vaccines tailored for a broad spectrum of farm animals, including swine, bovines, goats, ovines, and poultry. Additionally, its product range encompasses inoculations for canines. Beyond its domestic reach, the firm also distributes its offerings to international markets, notably exporting to Vietnam, Pakistan, and Egypt. Established in 2004, this enterprise bases its principal operations in Jilin, China, and operates as a subsidiary entity of Securingium Holding Limited.
ZYBT financial snapshot
- Wall Street Score:
- 15/100
- Current price:
- $1.38
- Market capitalization:
- $65.4M
- Revenue:
- $17.2M
- Net income:
- $-10.3M
- Free cash flow:
- $104K
- Cash:
- $7.4M
- Total debt:
- $11.1M
- EPS:
- -0.21
- Financial score:
- 12/100
- Valuation score:
- 0/100
- Revenue score:
- 2/100
What stands out
- Reported year-over-year revenue growth is -0.4%.
- Free cash flow is $104K, showing positive cash generation.
- The balance sheet shows $7.4M of cash versus $11.1M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 12/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research ZYBT
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.